The 11 most recent market catalysts affecting $CNTB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 75
Connect Biopharma Reports Third Quarter 2026 Financial Results and Business Update
Connect Biopharma reported its third-quarter 2026 financial results, which included an increase in R&D expenses due to rademikibart development. The key event disclosed is the comp…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4
Leerink Partners analyst Will Soghikian has initiated coverage on Connect Biopharma Holdings (CNTB) with an 'Outperform' rating and a $4 price target. This is a positive developmen…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 95
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma reported exceptionally strong Phase 2 results for its COPD therapy, rademikibart, showing an 81% reduction in treatment failure and eliminating hospital admission…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 85
Connect Biopharma shares are trading higher after the company announced preliminary topline data from its global Phase 2 study evaluating rademikibart. Results included Rademikibart reducing rate of treatment failure, rate of moderate to severe COPD exacerbations and reduced the rate of new emergency departments and hospital admissions.
The positive preliminary topline data for rademikibart in its global Phase 2 study is a major catalyst for Connect Biopharma. The reported reductions in treatment failure, COPD exa…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 85
Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%
Connect Biopharma announced highly positive topline results from its global Phase 2 study of Rademikibart as an add-on treatment for acute exacerbations in adult participants with …
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 65
Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
Oppenheimer's analyst Mazahir Alimohamed maintained an 'Outperform' rating for Connect Biopharma Holdings (CNTB), signaling continued confidence in the company's long-term prospect…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
The filing indicates that BTIG analyst Julian Harrison has reaffirmed a 'Buy' rating and a $10 price target for Connect Biopharma Holdings (CNTB). This is a routine analyst action …
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 95
Connect Biopharma Holdings shares are trading lower after the company announced topline results from its global phase 2 study evaluating rademikibart. The endpoint did not reach statistical significance.
The failure of a Phase 2 clinical trial for a lead drug candidate is a major negative catalyst for a biotechnology company. This directly impacts Connect Biopharma's valuation as t…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo
This headline is a significant corporate catalyst for Connect Biopharma. The 66% reduction in treatment failure is a strong signal of efficacy, which could be very positive for the…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo
Connect Biopharma released interim topline data from its Phase 2 Seabreeze STAT asthma trial for rademikibart, an anti-IL-4Rα antibody. The key findings include a statistically sig…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
Connect Biopharma Hldgs Q2 EPS $(0.27) Beats $(0.31) Estimate, Sales $2.768M Beat $650.000K Estimate
This headline indicates a significant positive catalyst for Connect Biopharma Holdings (CNTB). Beating both EPS and sales estimates by a considerable margin suggests better-than-ex…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.